Dynorphin

1. Overview

Dynorphin is a family of endogenous opioid neuropeptides derived from the precursor protein prodynorphin (encoded by the PDYN gene on chromosome 20p13), functioning as the principal endogenous agonist of the kappa opioid receptor (KOR). First isolated from porcine pituitary extracts in 1979 by Avram Goldstein and colleagues at Stanford University, dynorphin A (1-13) was described as "extraordinarily potent" -- over 700 times more potent than leucine-enkephalin in the guinea pig ileum bioassay -- inspiring the name "dynorphin" from the Greek dynamis (power) combined with endorphin [1][3].

The dynorphin family comprises several bioactive peptides generated by posttranslational proteolytic processing of the 254-amino-acid prodynorphin precursor by prohormone convertases PC1/3, PC2, and cathepsin L. These include dynorphin A (1-17), dynorphin B (1-13), big dynorphin (1-32) (the unsplit precursor containing both dynorphin A and B), alpha-neoendorphin, beta-neoendorphin, and leumorphin (dynorphin B 1-29) [3][25]. All prodynorphin-derived peptides share the N-terminal opioid "message" sequence Tyr-Gly-Gly-Phe-Leu (YGGFL), which is identical to leucine-enkephalin and responsible for opioid receptor activation. The C-terminal "address" domain, rich in basic residues (Arg-7, Lys-11, Lys-13), confers selectivity for the kappa opioid receptor over mu and delta subtypes [1][2][25].

Unlike the other two endogenous opioid peptide families -- beta-endorphin (from proopiomelanocortin, primarily activating mu opioid receptors to produce euphoria and reward) and enkephalins (from proenkephalin, primarily activating delta opioid receptors to modulate mood and pain) -- the dynorphin/KOR system encodes anti-reward, dysphoria, and aversive states [5][7]. This fundamental distinction places dynorphin at the center of a neurobiological opponent-process system: while mu-opioid signaling mediates the hedonic, rewarding aspects of experience, dynorphin/KOR signaling counterbalances this by encoding the negative affective consequences of stress, drug withdrawal, and chronic pain [7][8].

Dynorphin and its receptor are widely distributed throughout the central nervous system, with particularly high expression in the nucleus accumbens, dorsal striatum, amygdala, hypothalamus, hippocampus, prefrontal cortex, periaqueductal gray, and spinal cord dorsal horn [9][25]. This distribution pattern underlies dynorphin's involvement in an extraordinary range of functions: pain modulation, stress responses, mood regulation, reward processing, learning and memory, neuroendocrine function, and neuroprotection/neurotoxicity [3][15].

Full Name

Dynorphin A (1-17)

Sequence

Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln

One-Letter Code

YGGFLRRIRPKLKWDNQ

Peptide Length

17 amino acids (heptadecapeptide)

Molecular Weight

2147.52 Da

Molecular Formula

C99H155N31O23

Precursor

Prodynorphin (PDYN gene, chromosome 20p13)

Primary Receptor

Kappa opioid receptor (KOR/KOP)

Discovery

Avram Goldstein, Stanford University, 1979

Receptor Selectivity

KOR >> MOR > DOR

Key Function

Anti-reward, dysphoria, stress encoding, pain modulation

2. Discovery and Historical Context

The discovery of dynorphin emerged from the explosive growth in opioid peptide research that followed the identification of enkephalins by Hughes and Kosterlitz in 1975. The enkephalin discovery proved that the brain produces its own morphine-like substances, sparking an intense search for additional endogenous opioid peptides.

Avram Goldstein, a distinguished pharmacologist at Stanford University and the Addiction Research Foundation, had been studying opioid receptor heterogeneity and suspected that the recently identified kappa opioid receptor had its own endogenous ligand -- distinct from the enkephalins, which preferentially bound mu and delta receptors. In 1979, Goldstein and colleagues (Tachibana, Lowney, Hunkapiller, and Hood) reported the isolation of a novel opioid peptide from porcine pituitary that proved exceptionally difficult to purify. By sequencing the first 13 amino acids and synthesizing the fragment, they demonstrated potency over 700 times greater than leucine-enkephalin in the guinea pig ileum assay, with notably reduced sensitivity to naloxone antagonism (one-thirteenth that of normorphine) -- a pharmacological signature suggesting action at a non-mu receptor subtype [1].

Goldstein named the new peptide "dynorphin" -- combining the Greek word for power (dynamis) with the suffix -orphin (for endogenous morphine-like peptide) -- to reflect its extraordinary potency. The full 17-amino-acid sequence of dynorphin A was subsequently determined: Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln [1][3].

In 1982, Chavkin, James, and Goldstein published the definitive evidence that dynorphin is the specific endogenous ligand for the kappa opioid receptor, establishing the third canonical opioid peptide-receptor pairing alongside beta-endorphin/mu and enkephalin/delta [2]. The cloning of the prodynorphin gene in the early 1980s revealed the full complement of peptides derived from this precursor, and subsequent decades of research revealed that dynorphin's functions extend far beyond simple analgesia into the domains of stress, addiction, mood, and neurodegeneration [3].

The amino acid sequence of dynorphin A is remarkably conserved across species -- identical in humans, rats, mice, bovine, porcine, and amphibian species -- suggesting strong evolutionary pressure to maintain this peptide's structure and function [17].

3. Molecular Structure and Prodynorphin Processing

3.1 Dynorphin A Structure

Dynorphin A (1-17) is a heptadecapeptide with the following properties:

| Property | Value | |----------|-------| | Sequence | Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln | | One-letter code | YGGFLRRIRPKLKWDNQ | | Molecular weight | 2147.52 Da | | Molecular formula | C99H155N31O23 | | Isoelectric point | ~11.2 (highly basic) | | Net charge at pH 7 | +4 | | N-terminal motif | YGGFL (opioid "message" domain, shared with leu-enkephalin) | | C-terminal motif | RRIRPKLKWDNQ ("address" domain conferring KOR selectivity) |

NMR studies of dynorphin A bound to the human KOR reveal that the N-terminal YGGF "message" sequence is flexibly disordered, the central region from Leu-5 to Arg-9 forms a helical turn, and the C-terminal segment from Pro-10 to Lys-13 is flexibly disordered in the intermediate-affinity bound state. The strongly basic residues at positions 6, 7, 9, 11, and 13 interact electrostatically with acidic residues in the KOR extracellular loops, driving kappa subtype selectivity [25].

3.2 Prodynorphin Processing

The 254-amino-acid prodynorphin precursor undergoes sequential proteolytic cleavage at paired basic amino acid sites (Lys-Arg or Arg-Arg) by prohormone convertases PC1/3 and PC2, along with the cysteine protease cathepsin L, to generate the following bioactive peptides:

| Peptide | Residues | Sequence Features | |---------|----------|-------------------| | Big dynorphin | 1-32 | Contains complete Dyn A + Dyn B; generated by incomplete processing | | Dynorphin A (1-17) | 1-17 | Most potent KOR agonist; primary form | | Dynorphin A (1-8) | 1-8 | Truncated form with reduced potency | | Dynorphin B (1-13) | 1-13 | Also known as rimorphin; moderate KOR affinity | | Alpha-neoendorphin | 10 aa | KOR-preferring, with some mu activity | | Beta-neoendorphin | 9 aa | Lower potency variant of alpha-neoendorphin | | Leumorphin | 1-29 | Extended dynorphin B; includes C-terminal extension |

Cathepsin L plays a particularly important role in dynorphin processing: knockout of cathepsin L in mouse brains reduced dynorphin A, dynorphin B, and alpha-neoendorphin levels by 75%, 83%, and 90%, respectively [3][25].

4. Pharmacokinetics

Endogenous CSF and Tissue Levels

Dynorphin A is present in human cerebrospinal fluid (CSF) at low picomolar concentrations under resting conditions (estimated 5 to 25 fmol/mL). These levels are elevated in several pathological states [17][25]:

• Chronic pain: CSF dynorphin A levels are elevated 2- to 5-fold in patients with chronic neuropathic pain compared to pain-free controls
• Spinal cord injury: Tissue dynorphin concentrations in the spinal cord increase dramatically (up to 50-fold) within hours of traumatic injury, reaching levels sufficient for NMDA receptor-mediated excitotoxicity
• Addiction: Postmortem studies of cocaine and alcohol abusers show elevated prodynorphin mRNA in the nucleus accumbens and caudate nucleus

Half-Life and Degradation

Dynorphin A has a plasma half-life of approximately 5 to 10 minutes -- intermediate between beta-endorphin (20-37 minutes) and enkephalins (1-2 minutes) [25]. Degradation occurs through multiple peptidase pathways:

• Aminopeptidases: Cleave the N-terminal Tyr1, generating des-Tyr-dynorphin (dynorphin 2-17), which retains NMDA receptor activity but loses opioid activity
• Dynorphin-converting enzyme (DCE): A metalloendopeptidase that cleaves at the Arg6-Arg7 bond, generating dynorphin A (1-6) and smaller fragments
• Cathepsin L and other thiol proteases: Contribute to synaptic dynorphin degradation
• Angiotensin-converting enzyme (ACE): Cleaves dynorphin A at several sites

The relatively rapid degradation of dynorphin A is consistent with its role as a local neuromodulator rather than a circulating hormone. Unlike beta-endorphin, which is released from the pituitary into systemic circulation, dynorphin is predominantly released locally within synaptic and perisynaptic spaces [25].

KOR Occupancy and Clinical Pharmacology

The concept of KOR occupancy is critical for understanding the dose-response of KOR-targeted therapeutics. PET imaging studies using the selective KOR radioligand [11C]LY2795050 have characterized KOR occupancy in the human brain [19]:

• Aticaprant 10 mg oral (clinical dose): Achieves 73% to 94% KOR occupancy in the human brain at steady state, indicating near-complete receptor blockade
• Aticaprant 2 mg oral: Achieves approximately 40-50% KOR occupancy
• norBNI (research tool): Achieves essentially 100% KOR occupancy due to pseudo-irreversible binding, with effects persisting for weeks after a single dose

These occupancy data explain the dose selection for clinical trials: 10 mg aticaprant achieves sufficient KOR blockade to produce antidepressant effects, while higher doses may not provide additional benefit given the already high occupancy levels.

5. Mechanism of Action

5.1 Kappa Opioid Receptor Signaling

Dynorphin exerts its primary biological effects through the kappa opioid receptor (KOR), a G protein-coupled receptor (GPCR) with seven transmembrane domains encoded by the OPRK1 gene. Upon dynorphin binding, KOR undergoes conformational changes that activate multiple intracellular signaling cascades [9][22][25]:

Gi/o protein signaling pathway:

• Activation of Gi/o heterotrimeric G proteins
• Inhibition of adenylyl cyclase, reducing cAMP levels
• Activation of G protein-gated inwardly rectifying potassium (GIRK) channels, hyperpolarizing the neuron
• Inhibition of voltage-gated calcium channels (N-type and P/Q-type), reducing presynaptic neurotransmitter release
• Net effect: inhibition of neuronal excitability and neurotransmitter release

Beta-arrestin/GRK signaling pathway:

• G protein-coupled receptor kinase (GRK3) phosphorylation of the KOR C-terminal tail
• Recruitment of beta-arrestin 2
• Receptor internalization via clathrin-coated pit endocytosis
• Activation of p38 MAPK signaling cascade
• Proposed to mediate the dysphoric and aversive components of KOR activation [5][22]

Biased agonism at KOR: A major conceptual advance in KOR pharmacology has been the recognition that different agonists can preferentially activate either the G protein or beta-arrestin pathway -- a phenomenon termed biased agonism or functional selectivity [11][22]. This has profound therapeutic implications:

• G protein-biased agonists (e.g., nalfurafine, the first approved KOR-targeting drug in Japan for uremic pruritus) are proposed to retain analgesic and antipruritic effects while minimizing dysphoria and sedation
• Arrestin-biased agonists (e.g., WMS-X600) preferentially recruit beta-arrestin signaling
• Cryo-EM structures determined in 2023 identified four amino acid residues (K227, C286, H291, and Y312) that play critical roles in determining signaling bias at KOR [11]

However, recent 2025 preclinical data have added important nuance: signaling bias did not consistently correlate with antinociceptive or side effect profiles of KOR agonists in vivo, and beta-arrestin2 knockout had no effect on U50,488-induced sedation, suggesting the therapeutic relevance of biased agonism at KOR is more complex than initially proposed [11].

5.2 Anti-Reward and Dopamine Modulation

The most distinctive functional consequence of dynorphin/KOR signaling is the suppression of mesolimbic dopamine transmission. KOR is densely expressed on dopaminergic neurons and their terminals in the ventral tegmental area (VTA) and nucleus accumbens (NAc). KOR activation:

1. Directly inhibits dopamine release from mesolimbic terminals in the NAc through presynaptic inhibition of calcium channels
2. Increases dopamine reuptake by enhancing dopamine transporter (DAT) activity
3. Reduces dopamine neuron firing in the VTA through somatodendritic hyperpolarization [8]

This potent anti-dopaminergic action underlies the core phenomenology of dynorphin/KOR activation: dysphoria (a state of unease, dissatisfaction, and anhedonia), aversion, and negative affect -- the opposite of the euphoria produced by mu-opioid receptor or dopamine-stimulating drugs [7][8].

5.3 Non-Opioid Actions: NMDA Receptor Interactions

A critical and clinically significant feature of dynorphin pharmacology is its capacity to act through non-opioid mechanisms, particularly at the NMDA glutamate receptor. At elevated concentrations -- such as those occurring after spinal cord injury or in chronic pain states -- dynorphin A produces neurotoxic effects that are:

• Not blocked by opioid receptor antagonists (naloxone)
• Blocked by NMDA receptor antagonists (MK-801, AP-5)
• Mediated by direct binding of dynorphin's basic C-terminal residues to acidic residues on the NR1 subunit of the NMDA receptor, potentiating glutamate currents and causing excitotoxic calcium influx [16][17][21]

This dual pharmacology means that dynorphin A can have paradoxical effects on neuronal viability: at physiological concentrations, KOR-mediated signaling is neuroprotective (by reducing intracellular calcium through inhibition of calcium channels); at pathological concentrations, NMDA-mediated excitotoxicity produces neuronal death [17][21].

6. Dose-Response Relationships

Dysphoria Dose-Response

The dysphoric effects of KOR activation follow a dose-dependent pattern that has been characterized in both preclinical and clinical pharmacology:

Preclinical dose-response (rodent models):

• Low KOR activation (10-20% occupancy): Minimal behavioral effects; may produce subtle anxiogenic behavior detectable only in sensitive assays
• Moderate KOR activation (30-50% occupancy): Measurable conditioned place aversion; reduced intracranial self-stimulation thresholds (indicating reduced reward sensitivity); decreased sucrose preference (anhedonia)
• High KOR activation (70-90% occupancy): Robust conditioned place aversion; pronounced sedation; suppression of locomotor activity; potent anti-reward effects blocking cocaine and alcohol conditioned place preference
• Supramaximal KOR activation: Sedation, catalepsy, and in some species, hallucinatory-like behaviors

Human dose-response (salvinorin A as KOR agonist probe): Salvinorin A, the potent non-peptide KOR agonist from Salvia divinorum, provides the most direct human evidence for KOR dose-response [13][23]:

• 200-500 mcg inhaled: Mild perceptual disturbances, time distortion
• 500-1000 mcg inhaled: Moderate dysphoria, depersonalization, visual distortions
• 1000-2000 mcg inhaled: Intense dysphoria, hallucinations, complete detachment from reality, profound aversion
• Effects are dose-dependent, short-lasting (5-15 minutes), and universally rated as aversive by naive subjects

KOR antagonist dose-response for antidepressant effect: In the Phase 2 aticaprant trial for MDD, the dose-response suggests an inverted-U relationship between KOR blockade and clinical efficacy [19]:

• 2 mg aticaprant (approximately 40-50% KOR occupancy): Not formally tested in MDD
• 10 mg aticaprant (73-94% KOR occupancy): Statistically significant MADRS improvement (delta -2.1 points vs. placebo); greater effect in anhedonic subgroup (delta -4.0 points)
• Higher doses have not been tested, but near-complete occupancy at 10 mg suggests limited additional benefit from dose escalation

Analgesic vs. Pronociceptive Dose-Response

Dynorphin demonstrates a unique biphasic dose-response for pain modulation that reflects its dual opioid/NMDA pharmacology [16][17][20]:

Spinal analgesia (intrathecal administration in rodents):

• 0.1 to 1 nmol: Dose-dependent analgesia mediated by KOR activation, blocked by norBNI
• 1 to 10 nmol: Transitional zone where analgesic and pronociceptive effects overlap
• 10 to 30 nmol: Long-lasting allodynia and hyperalgesia mediated by NMDA receptor activation, blocked by MK-801 but NOT by naloxone

This dose-response dichotomy has direct clinical implications: the therapeutic window for KOR-mediated analgesia is narrow, and pathological dynorphin elevations (as in neuropathic pain and spinal cord injury) overshoot this window into the NMDA-mediated pronociceptive range.

7. Researched Applications

7.1 Addiction, Withdrawal, and Stress-Induced Relapse

Evidence level: Strong (extensive preclinical evidence; clinical trials of KOR antagonists)

The dynorphin/KOR system is now recognized as a central mechanism in the neurobiology of addiction, particularly in the transition from recreational drug use to compulsive drug seeking. The foundational work of Charles Chavkin and George Koob established a model in which dynorphin functions as a key component of the brain's "anti-reward" system [5][7][12]:

During drug binge consumption: Repeated activation of the mesolimbic dopamine system by drugs of abuse (cocaine, opioids, alcohol, psychostimulants) triggers a compensatory upregulation of dynorphin expression in the nucleus accumbens and dorsal striatum. This dynorphin release activates KOR on dopamine terminals, suppressing dopamine release and producing the dysphoric, anhedonic state characteristic of drug withdrawal [7][12].

During withdrawal: The elevated dynorphin tone persists beyond the acute drug effects, contributing to the negative emotional state (dysphoria, anxiety, irritability, anhedonia) that characterizes the withdrawal syndrome. This negative affect creates powerful motivation to resume drug taking to alleviate the dysphoria -- the "dark side" of addiction [7].

Stress-induced relapse: In landmark experiments, Chavkin and colleagues demonstrated that behavioral stress produces conditioned place aversion in mice through dynorphin/KOR activation, and that this aversion is absent in prodynorphin knockout mice or in wild-type mice pretreated with KOR antagonists [6]. Stress-induced reinstatement of drug seeking -- a model of relapse -- is consistently blocked by KOR antagonists such as norBNI and JDTic in animal models of cocaine, alcohol, and nicotine addiction [5][7][14].

These findings have driven the clinical development of KOR antagonists as anti-relapse therapies. Aticaprant combined with naltrexone has shown efficacy in preventing alcohol "relapse" drinking in preclinical models [19].

7.2 Depression and Anhedonia

Evidence level: Moderate-to-Strong (robust preclinical evidence; Phase 2 clinical data)

The dynorphin/KOR system has emerged as a major non-monoaminergic target for the treatment of depression, particularly anhedonia (the inability to experience pleasure), which is poorly addressed by conventional serotonergic antidepressants [18][24].

The mechanistic rationale is compelling: chronic stress increases CREB (cAMP response element-binding protein) activity in the nucleus accumbens, which drives elevated prodynorphin gene expression. The resulting increase in dynorphin release chronically suppresses mesolimbic dopamine transmission, producing the core depressive symptoms of anhedonia, amotivation, and dysphoria [18].

Preclinical evidence is extensive. KOR antagonists produce robust antidepressant- and anxiolytic-like effects in multiple animal models, including the forced swim test, learned helplessness, chronic mild stress, and social defeat paradigms [5][18]. Prodynorphin knockout mice are resilient to stress-induced depressive behaviors [6].

Clinical translation initially advanced with aticaprant (formerly JNJ-67953964/CERC-501/LY-2456302), a selective KOR antagonist with 30-fold selectivity for KOR over mu and delta receptors. In a Phase 2 randomized, double-blind, placebo-controlled trial of 181 patients with MDD and inadequate response to SSRI/SNRI therapy, adjunctive aticaprant (10 mg/day) produced statistically significant improvement in MADRS total score versus placebo (difference 2.1 points, p = 0.04), with greater effect in the anhedonic subgroup [19]. However, in March 2025, Johnson & Johnson discontinued development of aticaprant for MDD after it failed to demonstrate efficacy over placebo in Phase 3 trials, marking a significant setback for the KOR antagonist class in depression therapeutics. Navacaprant, another selective KOR antagonist being developed as monotherapy for MDD, continues in clinical development but the aticaprant failure has raised questions about the viability of KOR antagonism as an antidepressant strategy.

An earlier approach using ALKS 5461 (buprenorphine/samidorphan combination, targeting both mu and kappa receptors) showed efficacy in Phase 2 trials for treatment-resistant depression, but failed to replicate in Phase 3 and was rejected by the FDA [24].

7.3 Pain Modulation

Evidence level: Strong (well-established preclinical and clinical relevance)

Dynorphin plays a complex and context-dependent role in pain processing that distinguishes it from classical analgesic opioid systems [16][17][20]:

Spinal analgesia: At physiological concentrations, dynorphin released from interneurons in the spinal cord dorsal horn (laminae I/II and V) acts on presynaptic KOR to inhibit the release of excitatory neurotransmitters (glutamate, substance P, CGRP) from primary afferent C-fiber and A-delta fiber terminals, producing analgesia. This spinal KOR-mediated mechanism represents a genuine inhibitory pain control pathway [20][25].

Chronic pain pathology: Paradoxically, in chronic pain states (neuropathic pain, inflammatory pain), prodynorphin expression in the spinal cord is markedly upregulated. The resulting elevated dynorphin levels exceed the capacity of KOR-mediated inhibition and begin to act through non-opioid, NMDA receptor-mediated mechanisms to produce allodynia (pain from normally non-painful stimuli) and hyperalgesia (exaggerated pain responses) [16][17]. Spinally administered dynorphin A produces long-lasting allodynia that is blocked by NMDA antagonists but not by naloxone, demonstrating the non-opioid nature of this pronociceptive effect [16].

Affective dimension of pain: KOR activation in supraspinal regions (amygdala, anterior cingulate cortex) contributes to the aversive, dysphoric component of pain -- the suffering associated with chronic pain rather than the sensory intensity. KOR antagonists have shown efficacy in reducing the affective-motivational dimension of pain in preclinical models [20].

7.4 Spinal Cord Injury and Neurodegeneration

Evidence level: Moderate (preclinical studies)

Dynorphin A levels increase dramatically following spinal cord trauma, and this elevation contributes to secondary neurodegeneration -- the progressive expansion of tissue damage beyond the initial injury site [17]. The mechanism involves the dual pharmacology of dynorphin:

• At pathological concentrations following injury, dynorphin A activates NMDA receptors through its basic C-terminal domain, producing excitotoxic calcium influx and neuronal death
• C-terminal fragments of dynorphin A (e.g., dynorphin 2-17, which lacks the N-terminal tyrosine required for opioid receptor activation) are intrinsically neurotoxic through NMDA-mediated mechanisms [17][21]

Mutations in the prodynorphin gene that alter dynorphin A secondary structure are causative for spinocerebellar ataxia type 23 (SCA23), a neurodegenerative disorder. These mutations result in loss of normal KOR signaling and a gain of NMDA receptor-mediated excitotoxicity, directly linking dynorphin pathology to cerebellar neurodegeneration in humans [17].

Research on neuroprotective strategies has explored NMDA receptor antagonists and "decoy peptides" that bind dynorphin noncovalently to prevent its interaction with NMDA receptors, successfully blocking neurotoxicity in vitro [21].

7.5 Stress, Anxiety, and PTSD

Evidence level: Moderate (strong preclinical evidence; early clinical translation)

The dynorphin/KOR system is a critical mediator of the behavioral and affective consequences of stress. Corticotropin-releasing factor (CRF), the master stress hormone of the HPA axis, activates dynorphin release in stress-responsive brain regions including the amygdala, bed nucleus of the stria terminalis (BNST), and nucleus accumbens [5][7].

Chavkin and colleagues demonstrated in their landmark 2008 study that repeated forced swim stress and inescapable footshock in mice produced conditioned place aversion (a behavioral measure of dysphoria) that was completely blocked by the KOR antagonist norBNI and entirely absent in prodynorphin knockout mice [6]. This established the principle that the dysphoric component of the stress response is encoded by the dynorphin/KOR system.

The interaction between CRF and dynorphin creates a feedforward loop relevant to PTSD and trauma-related disorders: traumatic stress activates CRF release, which drives dynorphin expression, which produces dysphoria and anxiety, which further sensitizes stress circuits [5]. KOR antagonists have shown anxiolytic effects in multiple preclinical models and represent a potential novel therapeutic approach for anxiety disorders and PTSD.

8. Clinical Evidence Summary

9. Comparative Effectiveness: Dynorphin vs. Beta-Endorphin vs. Enkephalins

9.1 The Three Endogenous Opioid Families

The three classical endogenous opioid peptide systems arise from distinct precursor genes, exhibit different receptor preferences, and serve fundamentally different physiological roles:

| Feature | Dynorphin | Beta-Endorphin | Enkephalins | |---------|-----------|----------------|-------------| | Precursor | Prodynorphin (PDYN) | POMC (proopiomelanocortin) | Proenkephalin (PENK) | | Primary receptor | Kappa (KOR) | Mu (MOR) | Delta (DOR) | | Length | 17 aa (Dyn A) | 31 aa | 5 aa (Met-/Leu-Enk) | | N-terminal motif | YGGFL | YGGFM | YGGFM / YGGFL | | Plasma half-life | 5-10 minutes | 20-37 minutes | 1-2 minutes | | Core affective function | Dysphoria, anti-reward | Euphoria, reward | Anxiolysis, mood modulation | | Dopamine effect | Suppresses DA release | Enhances DA release | Modulates DA circuits | | Pain role | Dual: analgesia (spinal) and pronociception (chronic) | Potent supraspinal analgesia | Spinal and local analgesia | | Non-opioid activity | NMDA receptor excitotoxicity at high concentrations | None significant | OGF-OGFr growth regulation | | Stress response | Encodes dysphoric component | Mediates stress-induced analgesia | Modulates stress reactivity | | Therapeutic targeting | KOR antagonists for depression, addiction | Biomarker; exercise research | Enkephalinase inhibitors; LDN | | Discovery | Goldstein, 1979 | Li and Chung, 1976 | Hughes and Kosterlitz, 1975 |

The opponent-process framework: The most important conceptual distinction is the hedonic opposition between the three systems. Beta-endorphin/MOR encodes the rewarding, euphoric "bright side" of experience. Dynorphin/KOR encodes the aversive, dysphoric "dark side." Enkephalins/DOR provide a modulatory, anxiolytic middle ground. This opponent-process organization is not merely pharmacological -- it represents a fundamental architectural principle of emotional regulation in the brain, where hedonic balance depends on the relative tone of these three systems.

9.2 Dynorphin vs. Salvinorin A

Salvinorin A, a neoclerodane diterpene isolated from the plant Salvia divinorum, is the most potent naturally occurring non-peptide KOR agonist and has become an important pharmacological tool for understanding the dynorphin/KOR system [13][23]:

| Feature | Dynorphin A | Salvinorin A | |---------|------------|--------------| | Chemical class | Peptide (17 amino acids) | Neoclerodane diterpene (non-nitrogenous) | | Molecular weight | 2147.52 Da | 432.46 Da | | Receptor selectivity | KOR >> MOR > DOR | KOR only (no affinity for MOR, DOR, or 50+ other receptors) | | Efficacy | Full agonist | Full agonist (greater efficacy than Dyn A 1-13 under low receptor reserve) | | Non-opioid effects | NMDA receptor-mediated neurotoxicity | None identified | | Duration | Minutes (rapid enzymatic degradation) | Very short (minutes; rapid esterase metabolism) | | Subjective effects in humans | Endogenous (not administered) | Intense dysphoria, perceptual distortions, hallucinations | | Significance | Endogenous KOR ligand | First non-nitrogenous opioid-selective compound; pharmacological probe |

The profound dysphoric and hallucinogenic effects of salvinorin A in humans dramatically illustrate the subjective consequences of potent KOR activation, and reinforce the anti-reward function of the endogenous dynorphin/KOR system [13][23].

10. KOR Antagonists in Development

The therapeutic rationale for KOR antagonism -- blocking the dynorphin-mediated anti-reward, dysphoric, and pro-relapse signals -- has driven an active drug development pipeline:

| Compound | Stage | Indication | Notes | |----------|-------|-----------|-------| | Aticaprant (JNJ-67953964) | Discontinued (March 2025) | MDD (adjunctive) | 30-fold KOR selectivity; positive Phase 2 but failed Phase 3; development halted by J&J [19] | | Navacaprant | Phase 2/3 | MDD (monotherapy) | Selective KOR antagonist; monotherapy development track | | Buprenorphine/samidorphan (ALKS 5461) | Failed Phase 3 | Treatment-resistant depression | Mixed mu partial agonist/KOR antagonist; FDA rejected application | | norBNI | Research tool | N/A | Long-acting KOR antagonist; pharmacological gold standard but impractical clinically (weeks-long duration) | | JDTic | Discontinued | Substance use disorders | Highly selective KOR antagonist; cardiac safety concerns halted development |

11. Safety Considerations

Dynorphin is an endogenous neuropeptide, and safety considerations relate primarily to (1) states of pathological dynorphin signaling, (2) pharmacological manipulation of the KOR, and (3) the dual opioid/non-opioid pharmacology of dynorphin at elevated concentrations.

Pathological dynorphin elevation: Chronically elevated dynorphin levels are associated with negative health outcomes across multiple domains: chronic pain (spinal dynorphin drives neuropathic pain maintenance), depression and anhedonia (excess KOR tone suppresses mesolimbic dopamine), addiction vulnerability (dynorphin-mediated dysphoria drives compulsive drug seeking), and neurodegeneration (NMDA-mediated excitotoxicity after spinal cord injury or in SCA23) [7][16][17][18].

KOR agonist risks: Exogenous KOR activation (by synthetic agonists or salvinorin A) produces dysphoria, sedation, perceptual disturbances (including hallucinations at high doses), diuresis, and psychotomimetic effects. These adverse effects have historically limited the clinical utility of KOR agonists, though G protein-biased agonists (e.g., nalfurafine) show improved side effect profiles [4][11][23].

KOR antagonist safety: KOR antagonists such as aticaprant demonstrated favorable safety profiles in clinical trials through Phase 3. In the Phase 2 MDD trial, aticaprant was well tolerated with most adverse events rated mild [19]. However, the Phase 3 failure (inability to separate from placebo on efficacy) led to discontinuation in March 2025, suggesting that while KOR antagonists are safe, their antidepressant efficacy may not be robust enough for clinical use. Theoretical concerns include potential interference with stress-coping mechanisms (given dynorphin's physiological role in stress adaptation) and possible effects on pain modulation.

Non-opioid neurotoxicity: At pathological concentrations, dynorphin A's interaction with NMDA receptors can produce excitotoxic neuronal death. This effect is independent of opioid receptor activation and represents a distinct toxicological mechanism relevant to spinal cord injury, stroke, and neurodegenerative conditions [16][17][21].

Prodynorphin genetic variants and disease risk: Polymorphisms in the PDYN gene have been associated with altered vulnerability to substance use disorders, epilepsy, and cognitive decline. The PDYN promoter region contains a functional 68-base-pair variable number tandem repeat (VNTR) polymorphism, where alleles with higher repeat numbers are associated with increased prodynorphin expression and elevated risk for opioid dependence, cocaine dependence, and temporal lobe epilepsy [14].

Interaction with other opioid systems: Because the mu, delta, and kappa opioid systems are reciprocally interconnected, pharmacological manipulation of one system inevitably affects the others. KOR antagonism may disinhibit dopamine pathways, potentially lowering the threshold for reward-seeking behavior. This theoretical risk must be balanced against the therapeutic benefits in depression and addiction, and has not been observed as a clinical concern in aticaprant trials to date [19].

12. Dosing in Research

Dynorphin is an endogenous neuropeptide not administered as a therapeutic agent. No clinical dosing exists. Research applications include:

• In vitro KOR binding assays: Dynorphin A (1-17) at 10^-10 to 10^-6 M concentrations
• Intrathecal administration (rodent pain models): 1-30 nmol to study spinal pain mechanisms [16]
• NMDA-mediated neurotoxicity studies: 10^-6 to 10^-4 M concentrations (supraphysiological) [17][21]
• Endogenous levels (human CSF): Reported in the low picomolar range; elevated in chronic pain states and after spinal cord injury

KOR antagonist dosing in clinical trials:

• Aticaprant: 10 mg once daily (oral) in Phase 2 MDD trial [19]
• norBNI (research only): 10-30 mg/kg in rodent studies; effects persist for weeks due to pseudo-irreversible KOR binding

13. Related Peptides

See also: Substance P, Oxytocin, Ziconotide (Prialt), Orexin-A

14. References

1. [1] Goldstein A, Tachibana S, Lowney LI, Hunkapiller M, Hood L. (1979). Dynorphin-(1-13), an extraordinarily potent opioid peptide. Proceedings of the National Academy of Sciences. DOI PubMed
2. [2] Chavkin C, James IF, Goldstein A. (1982). Dynorphin is a specific endogenous ligand of the kappa opioid receptor. Science. DOI PubMed
3. [3] Schwarzer C. (2009). 30 years of dynorphins--new insights on their functions in neuropsychiatric diseases. Pharmacology and Therapeutics. DOI PubMed
4. [4] Chavkin C. (2011). The therapeutic potential of kappa-opioids for treatment of pain and addiction. Neuropsychopharmacology. DOI PubMed
5. [5] Bruchas MR, Land BB, Chavkin C. (2010). The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Research. DOI PubMed
6. [6] Land BB, Bruchas MR, Lemos JC, Xu M, Melief EJ, Chavkin C. (2008). The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. The Journal of Neuroscience. DOI PubMed
7. [7] Chavkin C, Koob GF. (2016). Dynorphin, dysphoria, and dependence: the stress of addiction. Neuropsychopharmacology. DOI PubMed
8. [8] Tejeda HA, Bonci A. (2019). Dynorphin/kappa-opioid receptor control of dopamine dynamics. Neuropsychopharmacology. DOI PubMed
9. [9] Crowley NA, Kash TL. (2015). Kappa opioid receptor signaling in the brain: circuitry and implications for treatment. Progress in Neuro-Psychopharmacology and Biological Psychiatry. DOI PubMed
10. [10] Bruchas MR, Roth BL. (2016). New technologies for elucidating opioid receptor function. Trends in Pharmacological Sciences. DOI PubMed
11. [11] Che T, Majumdar S, Zaidi SA, Bhatt DK, et al. (2023). Molecular mechanism of biased signaling at the kappa opioid receptor. Nature Communications. DOI PubMed
12. [12] Shippenberg TS, Zapata A, Chefer VI. (2007). Dynorphin and the pathophysiology of drug addiction. Pharmacology and Therapeutics. DOI PubMed
13. [13] Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, Rothman RB. (2002). Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proceedings of the National Academy of Sciences. DOI PubMed
14. [14] Butelman ER, Yuferov V, Kreek MJ. (2012). Kappa-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction. Trends in Neurosciences. DOI PubMed
15. [15] Tejeda HA, Shippenberg TS, Henriksson R. (2012). The dynorphin/kappa-opioid receptor system and its role in psychiatric disorders. Cellular and Molecular Life Sciences. DOI PubMed
16. [16] Laughlin TM, Vanderah TW, Lashbrook J, Nichols ML, Ossipov M, Porreca F, Wilcox GL. (1997). Spinally administered dynorphin A produces long-lasting allodynia: involvement of NMDA but not opioid receptors. Pain. DOI PubMed
17. [17] Bhatt DK, Bhatt DK. (2015). Pathobiology of dynorphins in trauma and disease. Frontiers in Bioscience. DOI PubMed
18. [18] Knoll AT, Carlezon WA Jr. (2010). Dynorphin, stress, and depression. Brain Research. DOI PubMed
19. [19] Krystal AD, Pizzagalli DA, Smoski M, et al. (2024). Efficacy and safety of aticaprant adjunctive to oral SSRI/SNRI antidepressant in major depressive disorder. Neuropsychopharmacology. DOI PubMed
20. [20] Cahill CM, Taylor AM, Cook C, Ong E, Moron JA, Evans CJ. (2014). Does the kappa opioid receptor system contribute to pain aversion?. Frontiers in Pharmacology. DOI PubMed
21. [21] O'Connor KA, Bhatt DK. (2008). Decoy peptides that bind dynorphin noncovalently prevent NMDA receptor-mediated neurotoxicity. The Journal of Neuroscience. DOI PubMed
22. [22] Bruchas MR, Chavkin C. (2010). Kinase cascades and ligand-directed signaling at the kappa opioid receptor. Psychopharmacology. DOI PubMed
23. [23] Butelman ER, Kreek MJ. (2015). Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders. Frontiers in Pharmacology. DOI PubMed
24. [24] Lalanne L, Ayranci G, Kieffer BL, Lutz PE. (2014). The kappa opioid receptor: from addiction to depression, and back. Frontiers in Psychiatry. DOI PubMed
25. [25] Sirohi S, Bhatt DK, Walker BM. (2022). Fundamentals of the dynorphins/kappa opioid receptor system: from distribution to signaling and function. Handbook of Experimental Pharmacology. DOI PubMed